Results 181 to 190 of about 46,487 (292)

Japanese Cohort Study and Meta‐Analysis Demonstrate Significant Association Between Serotonin Transporter‐Linked Polymorphic Region and Schizophrenia

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
This study demonstrates a significant association between the 5‐HTTLPR polymorphism and schizophrenia risk. The short allele was significantly overrepresented in patients (OR = 1.39, p = 0.007), suggesting a potential contribution to schizophrenia risk.
Masao Miyachi, Toshiyuki Shirai, Shohei Okada, Kiriko Minami, Ryo Tsukamoto, Kentaro Mouri, Satoshi Okazaki, Ikuo Otsuka, Akitoyo Hishimoto   +8 more
wiley   +1 more source

The Efficacy of Lacosamide in the Treatment of Delirium Complicated With Ileus: Four Cases. [PDF]

Neuropsychopharmacol Rep
Sato S.
europepmc   +1 more source

Context‐Dependent Temporal Changes in Hypnotics Involved in Suicide Attempts

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Temporal changes in hypnotics involved in suicide attempts showed context‐dependent shifts. Dual orexin receptor antagonists increased significantly, while benzodiazepine involvement declined only in overdose‐related attempts. Melatonin receptor agonists showed no significant trend during 2020.
Taro Sasaki, Norio Sugawara, Motoharu Furukawa, Hirotaka Iwaki, Shiro Suda, Norio Yasui‐Furukori   +5 more
wiley   +1 more source

Dystrophinopathy with a DMD exon 49–50 deletion in a female patient who developed schizophrenia: An autopsy case

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mutations in DMD affect not only muscles but also the brain. Cases of schizophrenia with DMD mutations have been described previously. Although female dystrophinopathy often has a milder phenotype, some affected females also have intellectual disabilities and psychiatric disorders.
Shusei Arafuka, Youta Torii, Ayako Miwa, Itaru Kushima, Hirotaka Sekiguchi, Hiroshige Fujishiro, Chikako Habuchi, Hiroaki Miyahara, Yosuke Kawai, Ran Wei, Katsushi Tokunaga, Norio Ozaki, Mari Yoshida, Shuji Iritani, Yasushi Iwasaki, Masashi Ikeda   +15 more
wiley   +1 more source

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source

Antipsychotic Misuse: A Silent but Growing Public Health Hazard. [PDF]

Cureus
Bhardwaj S, Pathak K, McLenon M, Spector S, Tu K.   +4 more
europepmc   +1 more source

The importance of longitudinal evaluation using DAT‐SPECT in organophosphate‐induced toxic parkinsonism

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
We performed longitudinal evaluation using magnetic resonance imaging (MRI) and dopamine transporter single‐photon emission computed tomography (DAT‐SPECT) in a case of organophosphate‐induced toxic parkinsonism. Fluid‐attenuated inversion recovery (FLAIR) images showed bilateral striatal hyperintensity in the acute phase, followed by reduction of ...
Shuhei Nakao, Yoichiro Kogoh, Hideki Funahashi, Yusei Yanoma, Minako Azuma, Yasushi Ishida, Yoji Hirano   +6 more
wiley   +1 more source

Antipsychotic prescribing patterns and determinants in first-episode psychosis: a 2019-2024 cross-sectional study from Zambia. [PDF]

BMC Psychiatry
Moyo LT, Tembo TM, Maila B.
europepmc   +1 more source

Clinical dilemma of mood stabilizer augmentation in treatment‐resistant schizophrenia with residual phase: A case report of valproate‐associated hypoglycemia and cytopenia, and subsequent lithium response

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Abstract Background Mood stabilizer augmentation is frequently used in treatment‐resistant schizophrenia despite limited guideline recommendations. Evidence for its efficacy and safety in the residual phase, however, remains insufficient. Case Presentation A 49‐year‐old Japanese woman with treatment‐resistant residual schizophrenia exhibited persistent
Yoshiki Kasagi, Naomichi Okamoto, Reiji Yoshimura   +2 more
wiley   +1 more source

First-generation antipsychotic shortages in the United States: Utilization and switching patterns. [PDF]

Explor Res Clin Soc Pharm
Tabah A, Swamy N, English C.
europepmc   +1 more source